Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771563 | 1.00 | MAOB (0.51) | MAOBALOX5LTA4HPTGS1PTGS2 | |
| SCHEMBL773504 | 0.91 | MAOB (0.49) | MAOBALOX5LTA4HPTGS1PTGS2 | |
| SCHEMBL773503 | 0.91 | MAOB (0.49) | MAOBALOX5LTA4HPTGS1PTGS2 | |
| SCHEMBL2492807 | 0.87 | MAOB (0.53) | MAOBALOX5LTA4HPTGS1PTGS2 | |
| SCHEMBL15674164 | 0.82 | MEN1 (0.41) | PPARGPPARAL3MBTL1FFAR1PPARD | |
| SCHEMBL15674166 | 0.82 | MEN1 (0.41) | PPARGPPARAL3MBTL1FFAR1PPARD | |
| SCHEMBL4234514 | 0.82 | ALOX5 (0.55) | MAOBALOX5LTA4HPTGS1PTGS2 | |
| SCHEMBL9679724 | 0.79 | SOAT2 (0.45) | MAOBALOX5LTA4HPTGS1PTGS2 | |
| SCHEMBL9679714 | 0.79 | SOAT2 (0.45) | MAOBALOX5LTA4HPTGS1PTGS2 | |
| SCHEMBL9679782 | 0.78 | GPR34 (0.48) | MAOBALOX5LTA4HPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | MAOB 2789/4885ALOX5 3664/4885LTA4H 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.